Search

everythinglearnresearchcommunity

for

Search:↓

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Baricitinib is more effective than methotrexate for severe alopecia areata.

New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.

Tofacitinib, a hair regrowth treatment, may worsen acne.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Deleting the MAD2L1 gene in mice led to rapid tumor growth despite chromosomal instability.

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Glibenclamide slows breast cancer cell growth by stopping cell division.

Cepharanthine shows promise as a potential lung cancer treatment by effectively killing cancer cells.

ZD1839 can cause skin issues like acne and hair changes.

Greenly synthesized silver nanoparticles from lentils show strong anticancer and antimicrobial effects.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.

Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.

Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

Treating acute myeloid leukemia is challenging, especially in older adults, despite some advancements.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.